ARS Pharmaceuticals, Inc.
SPRY
$9.86
$0.313.25%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 106.79% | 97.13% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 106.79% | 97.13% | |||
| Cost of Revenue | 21.32% | 122.91% | |||
| Gross Profit | 221.87% | 70.56% | |||
| SG&A Expenses | 37.63% | 32.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 35.31% | 40.27% | |||
| Operating Income | -11.72% | -28.07% | |||
| Income Before Tax | -13.97% | -32.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.97% | -32.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.97% | -32.24% | |||
| EBIT | -11.72% | -28.07% | |||
| EBITDA | -11.55% | -28.29% | |||
| EPS Basic | -13.46% | -31.84% | |||
| Normalized Basic EPS | -13.46% | -24.65% | |||
| EPS Diluted | -13.46% | -31.84% | |||
| Normalized Diluted EPS | -13.46% | -24.65% | |||
| Average Basic Shares Outstanding | 0.45% | 0.31% | |||
| Average Diluted Shares Outstanding | 0.45% | 0.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||